Emu B, Kumar PN, Mills A, Berhe M, et al. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study. J Acquir Immune Defic Syndr 2025 Jun 4. doi: 10.1097/QAI.0000000000003699.
PMID: 40465394